Target intelligence / Profile preview

Actinium-225 (Ac-225)

Target: Ac-225
Molecular classification: Radioisotope, Alpha-emitting radionuclide

Overview

Actinium-225 (Ac-225) is a synthetic radioisotope of actinium, notable for its use as an ionising radiation emitter in targeted alpha therapy (TAT), particularly for cancer treatment. It emits high-energy alpha particles with a very short range in biological tissue, making it highly effective at destroying targeted cells while minimizing collateral damage to surrounding healthy tissues.

Other names: 225Ac

Mechanism of action

Emission of alpha particles causing double-strand DNA breaks in targeted cells.

Biological functions

Ionizing radiation emitterInduces DNA damageApoptosis induction

Disease associations

Cancer therapy

Safety considerations

RadiotoxicityOff-target toxicityRadioactive waste managementLimited global supplyComplex radiochemistry for drug conjugation

Beyond the preview

Go deeper on Actinium-225 (Ac-225).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actinium-225 (Ac-225).

Explore the full profile